

**REMARKS**

Claim 15 and new claims 17-32 are pending. Claims 14 and 16 are canceled.

New claims 17-32 are ultimately dependent on claim 15 and include the limitations of original claims 2-13, and therefore are fully supported. No new matter has been added.

The Examiner has indicated that the subject application contained claims directed to the following patentably distinct species of the claimed invention:

**Group I, claim(s) 1-13**, drawn to a therapeutic agent of formula (I).

**Group II, claim(s) 14-16**, drawn to method of treating COPD using a therapeutic agent of formula (I).

In response to the restriction requirement set forth in the Office Action mailed November 1, 2007, Applicant hereby **elects Group II, Claims 14-16**, drawn to a method of treating COPD using the therapeutic agent of Formula (I). Concerning the specie election requirement, Applicant would like to select the **compound No. 551** shown in Table 15 on the page 26 of the present specification. Compound No. 551 is relevant to all claims 14-16 and all new dependent claims 17-32, except for claim 21, which does not include compound no. 551.

In addition to making an election, the applicants have rewritten claim 15 in independent form and have added new claims 17-32, based on claims 2-13, which all depend from claim 15.


It is believed that all claims are now allowable.

Early and favorable examination is requested.

Dated: November 29, 2007

Respectfully submitted,

By

  
James E. Armstrong, IV

(Registration No.: 42,266)

EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(202) 478-7370

Attorneys/Agents For Applicant